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Neurofibromas typically are benign nerve sheath tumors of the peripheral nervous system, arising from Schwann cells, classically associated with neurofibromatosis type 1 (NF1, von Recklinghausen\'s disease). Two types of neurofibromas are known to develop in NF1: superficial dermal or cutaneous neurofibromas, composed of a single peripheral nerve, and deep plexiform neurofibromas, which involve multiple nerve fascicles. Dermal neurofibromas typically arise in the second decade of life, often coinciding with the appearance of puberty. Plexiform neurofibromas, on the other hand, are typically congenital lesions and tend to grow mainly in the first decade of life. Unlike dermal neurofibromas, plexiform neurofibromas on rare occasions have been known to undergo malignant transformation and to develop into malignant peripheral nerve sheath tumors, which are aggressive, almost uniformly fatal cancers \[[@B1], [@B2]\]. About 10% of patients with NF1 are seen to develop these tumors, either from a plexiform neurofibroma or without such precursors \[[@B3]\].

NF1 is a common neurocutaneous disorder with an incidence of approximately 1 in 3,000 individuals \[[@B4]\]. It is an autosomal dominant disorder with few cases of sporadic inheritance, caused by any of a number of mutations of the *Nf1* gene, mapped on chromosome 17q11.2. *Nf1* is a tumor suppressor gene and produces the protein neurofibromin, which in turn is responsible for downregulating Ras, another cell protein that is thought to promote cell growth and proliferation \[[@B2], [@B5]\]. Increased risk of tumorigenesis is only seen in the homozygous state \[[@B6]\]. *Nf1* has a high penetrance, and so most patients with the mutation have some clinical features. Current genetic testing is able to identify 95% of *Nf1* mutations \[[@B7]\]. However, genetic testing is usually unnecessary, since clinical features can establish the diagnosis in about 95% of cases.

According to the NIH, two of the following diagnostic criteria should be present to make the diagnosis of NF1: =6 café au lait macules, =2 neurofibromas of any type or 1 plexiform neurofibroma, freckling in the axillary or inguinal regions, optic glioma, =2 iris hamartomas (Lisch nodules), bony lesions (pseudoarthrosis), or a first-degree relative with NF1. This condition has variable clinical expressions with manifestations involving many systems, such as the skin, eyes, bones, nervous system and gastrointestinal tract. The disease is equally prevalent in all ethnic groups.

Gastrointestinal involvement has been documented in 25% of patients with NF1, mostly involving the stomach and small intestine \[[@B8], [@B9]\]. The involvement consists of (1) ganglioneuromas: hyperplasia and hypertrophy of the nerve plexuses and ganglionic cells in the mucosa, and/or (2) neurofibromas: hyperplasia of neuronal cells in the submucosa, muscularis propria or even from the serosa. Sometimes it is also associated with gastrointestinal stromal tumors with different degrees of neuronal and smooth muscle differentiation \[[@B8], [@B10]\].
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A 59-year-old black man with a history of controlled dyslipidemia, hypertension, depression, benign prostatic hyperplasia, erosive gastritis, chronic pain syndrome and degenerative joint disease presented for a routine screening colonoscopy. His medical history was also significant for bilateral hydroceles and one previous hospitalization 6 years before for community-acquired pneumonia. His medications included aspirin 81 mg daily, finasteride 5 mg daily, risperidone 6 mg daily, trazedone 100 mg daily, fluoxetine 40 mg daily, hydrochlorothiazide 25 mg daily, omeprazole 20 mg daily, and tramadol 50 mg three times per day. He did not have any significant history of abdominal pain or bloating, diarrhea or constipation, or any melena or hematochezia. The patient denied any recent episodes of fevers, chills, nausea, or vomiting. He reported a stable appetite and weight. He had no history of alcohol, smoking, or drug abuse. His family history did not include any neurofibromatosis or any gastrointestinal malignancies. Physical examination of the head, neck, lungs, heart, skin and other systems did not reveal any significant findings. Ophthalmological examination revealed no Lisch nodules. Laboratory examinations, including a complete blood count, metabolic panel, hepatic panel and coagulation tests were all within normal limits.

On colonoscopic examination, a 3 mm polyp was found in the transverse colon (**fig. [1](#F1){ref-type="fig"}**) and another 4 mm polyp in the descending colon; both were biopsied. The remainder of the colonoscopy did not reveal any additional abnormal macroscopic pathology. Histological examination of the descending colonic polyp revealed findings consistent with a tubular adenoma; however, multiple levels of the 3 mm transverse colon polyp revealed interlacing bundles of spindle cells extending into the lamina propria with comma-shaped nuclei consistent with findings seen in neurofibroma (**fig. [2](#F2){ref-type="fig"}**). Subsequent immunohistochemical stains were performed on the specimen, which disclosed that S100 was expressed in the majority of the cell nuclei, also compatible with neurofibroma. CD117 staining was performed twice but had to be voided because of tissue loss.
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In this case, the patient had no personal or familial history of neurofibromatosis, nor did he have any of the physical manifestations that define NF1. He presented for routine screening colonoscopy that detected two polyps, with subsequent histology revealing a neurofibroma, confirmed by S100 staining. This is the fourth reported case of isolated colonic neurofibroma in a patient without NF1, and only the second one found in an asymptomatic patient undergoing routine colorectal cancer screening\[[@B11],[@B12],[@B13]\]. Unfortunately, this patient was lost to follow-up and no repeat colonoscopies were performed. It was discovered later that he died of complications related to an aggressive lymphoma.

The clinical significance of isolated, intestinal neurofibromas has not been well established. No consensus has yet been reached in the medical community as to whether such lesions represent different phenotypic manifestations of neurofibromatosis or separate and distinct entities entirely \[[@B14]\]. Though typically benign lesions, they have been reported to undergo malignant transformation, particularly when associated with NF1 and in larger, plexiform lesions \[[@B15]\]. Though uncommon, there are reports in the literature of neurofibromas and nerve sheath tumors presenting as lymphomas \[[@B16], [@B17]\].

Gastrointestinal neurofibromas are usually asymptomatic, but may present with bleeding, anemia, or signs or symptoms of obstruction. Indications for evaluation of gastrointestinal complications in the setting of NF1 include unexplained anemia, weight loss, gastrointestinal bleeding, abdominal pain, emesis, chronic diarrhea or signs of malabsorption \[[@B10], [@B18]\]. Occasionally, isolated intestinal neurofibromas may be the initial sign of NF1 in patients without any other clinical manifestations of the disease. As discussed previously, NF1 is a tumor predisposition syndrome and thus requires some degree of surveillance, consisting mainly of regular, comprehensive physical examinations aimed at the early detection and treatment of complications as they occur \[[@B19]\]. This case highlights the need for close clinical follow-up of patients found to have isolated neurofibromas to exclude NF1, as isolated neurofibromas are rare entities and have an increased risk of malignant transformation when associated with NF1 \[[@B20]\].

![Photograph of a 3 mm polyp of the transverse colon, found on biopsy to be a neurofibroma.](crg-0006-0058-g01){#F1}

![Photomicrograph of a transverse colon polyp. A high-power field showed interlacing bundles of spindle cells, with comma-shaped nuclei, extending into the lamina propria, consistent with findings of a neurofibroma. Staining was positive for nuclear S100.](crg-0006-0058-g02){#F2}
